Abstract 14084: Empagliflozin in Hospitalized Patients With Heart Failure
Abstract
Introduction:
The sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended as part of guideline-directed medication therapy (GDMT) for those with heart failure (HF) and New York Heart Associated (NYHA) class II-IV symptoms. The 2022 AHA/ACC/HFSA HF guidelines recommend SGLT2i in those with HF and reduced ejection fraction (HFrEF), and to consider in those with mid-range or preserved ejection fraction (HFmrEF and HFpEF).
Hypothesis:
We aimed to evaluate the initiation of empagliflozin in patients hospitalized with HF to prove tolerability over other GDMT and continuation at discharge.
Methods:
This was a multi-center, retrospective review of empagliflozin initiation at 2 campuses of the same health system (NYU Langone Hospital-Long Island and NYU Langone Health) from November 2021 -October 2022. We included patients > 18 years of age with HF that received empagliflozin during hospitalization. Data collection included patient characteristics, empagliflozin dose, ejection fraction (EF), BNP, estimated glomerular filtration rate, and other GDMT including beta-blockers (BB), angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), angiotensin receptor/neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRA). The primary outcome was empagliflozin initiation per EF. Secondary outcomes included evaluation of GDMT and continuation of therapies at discharge.
Results:
In total 434 medical records were reviewed, with 244…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.